| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Michael Perdices | Q66764439 |
| P2093 | author name string | Christopher C Tennant | |
| Carissa M Coulston | |||
| P2860 | cites work | Delta 9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966. | Q48702127 |
| Caffeine: The forgotten variable | Q48707410 | ||
| Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain | Q28188520 | ||
| The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study | Q28207211 | ||
| Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists | Q28212355 | ||
| Causal association between cannabis and psychosis: examination of the evidence | Q28241735 | ||
| Schizophrenia | Q28267772 | ||
| A neurobiological basis for substance abuse comorbidity in schizophrenia | Q28347063 | ||
| Learning and memory impairment in cocaine-dependent and comorbid schizophrenic patients | Q28372074 | ||
| The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis | Q30047193 | ||
| Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction | Q30053550 | ||
| Poor premorbid school performance is associated with later cigarette smoking among schizophrenia patients. | Q30351628 | ||
| Magnetic resonance spectroscopy and schizophrenia: what have we learnt? | Q30629018 | ||
| Effects of smoking marijuana on brain perfusion and cognition. | Q30692479 | ||
| The relationship between brain structure and neurocognition in schizophrenia: a selective review | Q30954053 | ||
| Iowa gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders | Q31106608 | ||
| Neurocognitive functioning in recently abstinent, cocaine-abusing schizophrenic patients. | Q31440279 | ||
| Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia | Q33511742 | ||
| A review of the effects of nicotine on schizophrenia and antipsychotic medications | Q33743641 | ||
| Anandamide inhibition of recombinant AMPA receptor subunits in Xenopus oocytes is increased by forskolin and 8-bromo-cyclic AMP. | Q48906736 | ||
| Traumatic brain injury and schizophrenia in members of schizophrenia and bipolar disorder pedigrees | Q48965810 | ||
| Different effects of nabilone and cannabidiol on binocular depth inversion in Man. | Q51080370 | ||
| Self-reports by alcohol and drug abuse inpatients: factors affecting reliability and validity | Q51688871 | ||
| Effects of pharmacological therapy on gait and cognitive function in depressed patients. | Q51905105 | ||
| Screening for cognitive functioning in psychiatric outpatients with schizophrenia, alcohol dependence, and dual diagnosis. | Q51906881 | ||
| Substance misuse and cognitive functioning in early psychosis: a 2 year follow-up. | Q51913151 | ||
| Neuropsychological deficits in nonsmokers with schizophrenia: effects of a nicotinic antagonist. | Q51917938 | ||
| Cannabis use and psychosis. | Q51925370 | ||
| Correlates of substance abuse in adolescents with treatment-refractory schizophrenia and schizoaffective disorder. | Q51934012 | ||
| Neuropsychological deficits are associated with smoking cessation treatment failure in patients with schizophrenia. | Q51938027 | ||
| Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. | Q51974198 | ||
| CANTAB explicit memory is less impaired in addicted schizophrenia patients. | Q51991798 | ||
| Neurocognitive functioning and quality of life among dually diagnosed and non-substance abusing schizophrenia inpatients. | Q51995064 | ||
| Caffeine consumption in hospitalized psychiatric patients. | Q52010294 | ||
| Cognitive functioning of long-term heavy cannabis users seeking treatment. | Q52014109 | ||
| Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. | Q52016145 | ||
| Are schizophrenic men at higher risk for developmental deficits than schizophrenic women? Implications for adult neuropsychological functions. | Q52056233 | ||
| Executive and motor skill functioning among cocaine-dependent schizophrenics and non-drug-abusing schizophrenics. | Q52121982 | ||
| Nicotine-haloperidol interactions and cognitive performance in schizophrenics. | Q52199316 | ||
| Caffeine and schizophrenia. | Q52230951 | ||
| Attention and information processing in schizophrenia | Q52309232 | ||
| Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. | Q52582625 | ||
| Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. | Q52926271 | ||
| Neurocognitive function in alcoholic, schizophrenic, and dually diagnosed patients | Q57880912 | ||
| Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia | Q58190172 | ||
| Early-onset cannabis use and cognitive deficits: what is the nature of the association? | Q44360031 | ||
| Cognitive disparity in schizophrenics with and without cocaine dependency | Q44368428 | ||
| Systemic, but not local, administration of cannabinoid CB1 receptor agonists modulate prefrontal cortical acetylcholine efflux in the rat. | Q44398446 | ||
| Altered Behavioral Response to Dopamine D3 Receptor Agonists 7-OH-DPAT and PD 128907 Following Repetitive Amphetamine Administration | Q44407119 | ||
| Testing hypotheses about the relationship between cannabis use and psychosis | Q44487800 | ||
| Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up | Q44537020 | ||
| Reduced binocular depth inversion in regular cannabis users | Q44574413 | ||
| Detection of cannabinoid agonist evoked increase in BOLD contrast in rats using functional magnetic resonance imaging | Q44771407 | ||
| Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals | Q44779937 | ||
| Nicotine improves delayed recognition in schizophrenic patients | Q44784226 | ||
| Nicotine effects on brain function and functional connectivity in schizophrenia | Q44819469 | ||
| Cannabis use and psychosis: a longitudinal population-based study. | Q44820509 | ||
| Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. | Q44827846 | ||
| Nicotine reduces antisaccade errors in task impaired schizophrenic subjects | Q44849187 | ||
| Effects of nicotine on cognitive deficits in schizophrenia | Q44892553 | ||
| Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms | Q45049153 | ||
| Ecstasy/MDMA and cannabis: the complexities of their interactive neuropsychobiological effects. | Q45176545 | ||
| Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy. | Q45986606 | ||
| Neurocognition, symptomatology, and functional skills in older alcohol-abusing schizophrenia patients | Q46485919 | ||
| An evaluation of persisting cognitive effects after withdrawal from long-term benzodiazepine use. | Q46489363 | ||
| Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms | Q46531414 | ||
| Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain | Q46547524 | ||
| Neurocognitive functioning in dually diagnosed middle aged and elderly patients with alcoholism and schizophrenia | Q46568489 | ||
| Alcohol and drug use in schizophrenia as predictors of functional impairment | Q46591124 | ||
| Neuropsychological and sensory gating deficits related to remote alcohol abuse history in schizophrenia | Q46909505 | ||
| Neurocognitive function and outcome in first-episode schizophrenia: a 10-year follow-up of an epidemiological cohort | Q47372948 | ||
| Nicotinic receptor desensitization and sensory gating deficits in schizophrenia | Q47910862 | ||
| Sensory-perceptual dysfunction in patients with schizophrenia and comorbid alcoholism | Q48021429 | ||
| The functional neuroanatomy of brain cannabinoid receptors | Q48285221 | ||
| Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids | Q48383234 | ||
| Long-term cognitive impact of anticholinergic medications in older adults. | Q48386314 | ||
| Neuropsychological correlates of negative, disorganized and psychotic symptoms in schizophrenia | Q48418949 | ||
| Smoking and cognitive deficits in schizophrenia: a pilot study | Q48477063 | ||
| Neuropsychological correlates of positive vs. negative schizophrenic symptomatology | Q48502516 | ||
| Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors | Q48518726 | ||
| The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease | Q33772712 | ||
| Pharmacology and effects of cannabis: a brief review | Q33931252 | ||
| The time course and significance of cannabis withdrawal | Q33967997 | ||
| Neuropsychological performance in long-term cannabis users | Q34092892 | ||
| Pharmacokinetics and pharmacodynamics of cannabinoids | Q34185013 | ||
| Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study | Q34220050 | ||
| Sources of heterogeneity in schizophrenia: the role of neuropsychological functioning | Q34273792 | ||
| Cognitive impairment in substance abuse | Q34310848 | ||
| D3 dopamine receptor, behavioral sensitization, and psychosis | Q34376205 | ||
| Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings | Q34479691 | ||
| Effects of marijuana on neurophysiological signals of working and episodic memory | Q34623119 | ||
| The cognitive neuropsychiatric approach to investigating the neurobiology of schizophrenia and other disorders. | Q34778242 | ||
| In vivo imaging of the brain cannabinoid receptor | Q35035820 | ||
| Cannabis use and the risk of later schizophrenia: a review | Q35720869 | ||
| The cannabis withdrawal syndrome | Q36448206 | ||
| What have we learned from functional imaging studies in schizophrenia? The role of frontal, striatal and temporal areas | Q36820162 | ||
| Childhood head injury and expression of schizophrenia in multiply affected families | Q37176017 | ||
| Cocaine craving and attentional bias in cocaine-dependent schizophrenic patients | Q38418860 | ||
| Gestalt perception in schizophrenia | Q38474447 | ||
| Comorbid non-alcohol substance misuse among people with schizophrenia: epidemiological study in central London | Q39587016 | ||
| Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study | Q39680990 | ||
| Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers | Q40407073 | ||
| Effects of Cigarette Smoking on Psychopathology Scores in Patients With Schizophrenia: An Experimental Study | Q40617490 | ||
| Psychosis proneness and ADHD in young relatives of schizophrenia patients | Q40623589 | ||
| A simple (or simplistic?) cognitive model for schizophrenia | Q40769476 | ||
| Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence | Q40980949 | ||
| Chronic psychiatric patients' use of caffeine: pharmacological effects and mechanisms | Q41035105 | ||
| Caffeine and its effect on persons with mental disorders | Q41233168 | ||
| Seizures and schizophrenia | Q41640680 | ||
| Clozapine-induced electroencephalogram changes as a function of clozapine serum levels | Q42548854 | ||
| A proposed pathological model in the hippocampus of subjects with schizophrenia | Q43518186 | ||
| Response inhibition and cognitive flexibility in schizophrenia with and without comorbid substance use disorder | Q43520161 | ||
| Cannabinoids of diverse structure inhibit two DOI-induced 5-HT(2A) receptor-mediated behaviors in mice | Q43553260 | ||
| Reducing the harms caused by cannabis use: the policy debate in Australia | Q43570022 | ||
| Delta9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study | Q43653883 | ||
| Cannabis induced dopamine release: an in-vivo SPECT study | Q43744306 | ||
| Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics | Q43761135 | ||
| Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist but not antagonist binding to 5-HT2c receptors after chronic treatment | Q43761962 | ||
| Does cognitive function improve with quetiapine in comparison to haloperidol? | Q43819115 | ||
| Effects of smoking abstinence on visuospatial working memory function in schizophrenia | Q43829054 | ||
| A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography | Q43873915 | ||
| Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders | Q44041615 | ||
| Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia | Q44133505 | ||
| Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study | Q44182591 | ||
| Acute effects of cigarettes in non-deprived smokers on memory, calculation and executive functions | Q44204413 | ||
| P433 | issue | 11 | |
| P921 | main subject | neuropsychology | Q3872 |
| schizophrenia | Q41112 | ||
| P304 | page(s) | 869-884 | |
| P577 | publication date | 2007-11-01 | |
| P1433 | published in | Australian and New Zealand Journal of Psychiatry | Q4824838 |
| P1476 | title | The neuropsychology of cannabis and other substance use in schizophrenia: review of the literature and critical evaluation of methodological issues | |
| P478 | volume | 41 |
| Q39395711 | Association between tobacco smoking and cognitive functioning in young adults. |
| Q38039423 | Cannabinoids for the treatment of schizophrenia? A balanced neurochemical framework for both adverse and therapeutic effects of cannabis use. |
| Q50993509 | Cannabis and cognitive performance in psychosis: a cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings. |
| Q37643444 | Cannabis use and cognition in schizophrenia |
| Q34634045 | Cannabis use and cognitive dysfunction |
| Q44906174 | Cannabis use and cognitive functions in at-risk mental state and first episode psychosis |
| Q37544803 | Chronic toxicology of cannabis |
| Q47945952 | Cognitive functioning associated with stimulant use in patients with non-affective psychosis, their unaffected siblings and healthy controls |
| Q38124448 | Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings |
| Q92238326 | Early Substance Use Cessation Improves Cognition-10 Years Outcome in First-Episode Psychosis Patients |
| Q47739996 | Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls |
| Q39820721 | Effects of Δ-THC on Working Memory: Implications for Schizophrenia? |
| Q36577094 | Inferior performance on selected neuropsychological tests in abstinent schizophrenia patients who have used cannabis. |
| Q30681799 | Neuropsychology, social cognition and global functioning among bipolar, schizophrenic patients and healthy controls: preliminary data |
| Q51861083 | Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia. |
| Q46195474 | The case for policy reform in cannabis control |
| Q50980365 | The differential effect of illicit drug use on cognitive function in first-episode psychosis and healthy controls. |
| Q33641039 | The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample |
| Q51957715 | The role of cannabis in cognitive functioning of patients with schizophrenia. |
Search more.